



pharmerit
international

Pharmerit International
wishes you a pleasant
ISPOR 14th Annual
European Congress
in Madrid, Spain,
5-8 November 2011.

For further information:
Please visit our booth 67 - 68 and
the Pharmerit Sponsored Internet
Access Stations.

Rotterdam - York - Bethesda
www.pharmerit.com

access through evidence

Pharmerit's Staff Contributions to ISPOR 14th Annual European Congress

POSTER SESSION I, SUNDAY, 6 NOVEMBER, 12:00 – 20:00

PIN3	Comparing the efficacy and tolerability of anti-retroviral therapy in treatment-naïve HIV-1 infected adults: a systematic review of randomized clinical trials and Bayesian mixed treatment comparisons including atazanavir/r, darunavir/r, lopinavir/r, and efavirenz
PIN4	Clinical and economic burden of invasive fungal infection (IFI) in Europe: a review of the literature
PIN10	Clinical and economic burden of hospital onset health care facility acquired Clostridium difficile infection (HO-HCFA-CDI) in Europe: a systematic review
PIN30	Cost analysis of voriconazole versus itraconazole for prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic stem cell transplant (HSCT) in Canada, France, Germany, and the United States
PIN73	Modeling the long term clinical outcomes and health care cost impact of initiating treatment with atazanavir/r compared with darunavir/r, lopinavir/r and efavirenz for hiv-1 infected treatment-naïve patients: country results for Italy, Spain, Portugal and UK
PIN82	Cost-effectiveness of atazanavir/r compared to darunavir/r in Germany
PMH33	The cost-effectiveness of paliperidone ER in Spain
PND33	Cost minimization analysis of fingolimod compared to natalizumab in patients with relapse remitting multiple sclerosis in the Netherlands
PUK3	Sources of heterogeneity among overactive bladder clinical trial estimates of tolterodine and fesoterodine reductions of urgency urinary incontinence episodes relative to placebo
PUK5	Mixed treatment comparisons of immunosuppressants following renal transplant

POSTER SESSION II, MONDAY, 7 NOVEMBER, 8:00 – 19:30

PHP104	Identifying factors influencing drug reimbursement in Scotland
PCV87	Ticagrelor for the treatment of acute coronary syndromes (ACS): a Dutch analysis based on the PLATO trial

POSTER SESSION III, TUESDAY, 8 NOVEMBER, 8:00 – 16:00

PRM39	Identification of diseases for EQ-5D bolt-on item development: an empirical approach
PCN44	Cost-of-illness study of human papillomavirus cancers in England
PCN73	Cost effectiveness of zoledronic acid versus pamidronate or no therapy for the treatment of bone metastases secondary to prostate cancer
PDB50	Reduction in comorbidities and cost savings associated with biochemical control in patients with Cushing's disease: a literature-based analysis
PRS9	Budget impact analysis of immunotherapy in patients with grass pollen allergic rhinitis
PRS11	Budget impact analysis of immunotherapy in patients with birch allergic rhinitis
PRS41	Cost-effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinitis

PODIUM SESSION I, MONDAY, 7 NOVEMBER, 11:30 – 12:30

	New approaches for effective use of data: better synthesis and enhanced power
DA3	The power of assumptions

PODIUM SESSION II, MONDAY, 7 NOVEMBER, 15:15 – 16:15

	Merging pro and utility assessment: does the gap indeed get smaller?
UT1	Combining DCE and TTO into a single value function

WORKSHOPS SESSION II, SUNDAY, 6 NOVEMBER, 17:15 – 18:15

	Patient-reported outcomes & preference-based research
W14	Valuing health in economic evaluations; innovative responses to methodological challenges

Pharmerit Europe

Bart Heeg
Marten Meesweg 107
3068 AV Rotterdam - The Netherlands
Main +31-10-4519924
Fax +31-10-4421158
bheeg@pharmerit.com

Pharmerit United Kingdom

Stephanie Thurston
Tower House, Suite 8 - Fishergate, York
YO10 4UA, United Kingdom
Main +44-(0)1904-567373
Fax +44-(0)1904-567334
sthurston@pharmerit.com

Pharmerit North America

Marc Botteman
4350 East West Highway, Suite 430
Bethesda MD 20814 - United States
Main +1-240-8211265
Fax +1-240-8211296
mbotteman@pharmerit.com